GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (STU:8AK) » Definitions » Debt-to-Revenue

Alkermes (STU:8AK) Debt-to-Revenue : 0.26 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Alkermes Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Alkermes's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €8 Mil. Alkermes's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €332 Mil. Alkermes's annualized Revenue for the quarter that ended in Mar. 2024 was €1,289 Mil. Alkermes's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.26.


Alkermes Debt-to-Revenue Historical Data

The historical data trend for Alkermes's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Debt-to-Revenue Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.40 0.36 0.34 0.22

Alkermes Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.16 0.25 0.25 0.26

Competitive Comparison of Alkermes's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Alkermes's Debt-to-Revenue falls into.



Alkermes Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Alkermes's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(8.02 + 333.274) / 1525.342
=0.22

Alkermes's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(8.197 + 332.301) / 1289.368
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Alkermes Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alkermes's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (STU:8AK) Business Description

Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Alkermes (STU:8AK) Headlines

No Headlines